BioCentury | Jan 20, 2021
Emerging Company Profile

Aulos: Tackling the IL-2 space with computational biology

...through its acquisition of Synthorx Inc., and Alkermes plc...
BioCentury | Jan 15, 2021
Management Tracks

Frates joins ALS company Amylyx; plus Artios, Valneva, Viravaxx

...By BioCentury Staff After two decades at Alkermes plc (NASDAQ:ALKS), James Frates will join neurodegenerative diseases company Amylyx Pharmaceuticals Inc...
...in 2019, helped raise millions of dollars to fight the disease via the Ice Bucket Challenge. Alkermes...
BioCentury | Jan 15, 2021
Product Development

Jan. 14 Quick Takes: Pancreatic cancer data lifts NantKwest; plus NIH-Alkermes, Abbott, Inzen

...reported data from the Phase III ADAPT-2 trial that a combination of Vivitrol naltrexone from Alkermes plc...
BioCentury | Jan 7, 2021
Management Tracks

Alkermes promotes two to oversee growth plan as CFO Frates departs

...By Jeff Cranmer, Executive Editor As James Frates prepares to depart Alkermes after two decades, the...
...unveiled in December in the wake of discussions with activist investor Elliott Advisors.Frates, who joined Alkermes plc...
...a six-year stint at San Francisco wealth management firm Robertson Stephens, will pursue another opportunity. Alkermes...
BioCentury | Dec 31, 2020
Regulation

Dec. 30 Quick Takes: A first for Chi-Med; plus Orphazyme, BMS, FDA REMS, Pfizer, Astellas, Alkermes, Osmotica, Quanterix, Ampio and Novartis

...Audentes Therapeutics Inc., an Astellas Pharma Inc. (Tokyo:4503) company, is in development for X-linked myotubular myopathy.Alkermes’...
...3831 returns to FDA for review FDA has accepted an NDA resubmission for ALKS 3831 from Alkermes plc...
BioCentury | Dec 15, 2020
Finance

Dec. 14 Quick Takes: Locanabio raises $100M series B; plus rare bleeding disorder newco Hemab, raises for Rani, CG, InnoSkel, Denovo, Biosion and more

...Partners Acquisition Corp. (NASDAQ:BRPA), a special purpose acquisition company. SPACs re-emerged this year as a viable IPO alternative.Alkermes...
...Healthcare Fund Zheshang Innovest HighTide Therapeutics Inc. Greater Bay Area Homeland Development Fund Hangzhou Tigermed Consulting Co. Ltd. Citic Securities NeuroRx Inc. Alkermes plc China...
BioCentury | Nov 17, 2020
Regulation

Alkermes expects quick resolution to FDA setback for antipsychotic

...By Paul Bonanos, Associate Editor Alkermes expects a swift resolution to a manufacturing issue that led...
...3831, but the company isn’t yet committing to a launch timeline for the antipsychotic combination therapy.Alkermes plc...
...buprenorphine.Alkermes closed up $0.45 to $18.30 on Tuesday.TARGETSMOR (OPRM1) - μ opioid receptor Paul Bonanos samidorphan/olanzapine (ALKS 3831) Alkermes plc...
BioCentury | Oct 12, 2020
Finance

Priothera raises €30 million to develop onetime Novartis candidate in AML transplantation setting

...acquired. The firm had backed Civitas Therapeutics Inc., which housed a Parkinson’s disease program from Alkermes plc...
BioCentury | Oct 10, 2020
Product Development

Oct. 9 Quick Takes: Sobi’s Phase III miss; plus Alkermes, COVAX, Warp Speed-AZ, Lilly-Gates, Pfizer, Everest and Affamed-Kissei

...rights via its $915 million takeout of Dova Pharmaceuticals Inc. last year. FDA panel: labeling sufficient to mitigate Alkermes...
...associated with opioid antagonist action of samidorphan, one of the components of ALKS 3831 from Alkermes plc...
BioCentury | Oct 8, 2020
Product Development

COVAX nears $2B fund-raising goal for equitable vaccine distribution; plus Novartis-Merck KGaA, 10x Genomics, Alkermes, UCB-Aetion, Janpix, BeiGene-BioAtla, Phenomic AI

...CartaNA AB, which is developing in situ RNA analysis technology. FDA to discuss safety, efficacy of Alkermes’...
...disorder candidateBriefing documents released ahead of Friday’s FDA advisory committee meeting to discuss olanzapine/samidorphan from Alkermes plc...
Items per page:
1 - 10 of 1179
BioCentury | Jan 20, 2021
Emerging Company Profile

Aulos: Tackling the IL-2 space with computational biology

...through its acquisition of Synthorx Inc., and Alkermes plc...
BioCentury | Jan 15, 2021
Management Tracks

Frates joins ALS company Amylyx; plus Artios, Valneva, Viravaxx

...By BioCentury Staff After two decades at Alkermes plc (NASDAQ:ALKS), James Frates will join neurodegenerative diseases company Amylyx Pharmaceuticals Inc...
...in 2019, helped raise millions of dollars to fight the disease via the Ice Bucket Challenge. Alkermes...
BioCentury | Jan 15, 2021
Product Development

Jan. 14 Quick Takes: Pancreatic cancer data lifts NantKwest; plus NIH-Alkermes, Abbott, Inzen

...reported data from the Phase III ADAPT-2 trial that a combination of Vivitrol naltrexone from Alkermes plc...
BioCentury | Jan 7, 2021
Management Tracks

Alkermes promotes two to oversee growth plan as CFO Frates departs

...By Jeff Cranmer, Executive Editor As James Frates prepares to depart Alkermes after two decades, the...
...unveiled in December in the wake of discussions with activist investor Elliott Advisors.Frates, who joined Alkermes plc...
...a six-year stint at San Francisco wealth management firm Robertson Stephens, will pursue another opportunity. Alkermes...
BioCentury | Dec 31, 2020
Regulation

Dec. 30 Quick Takes: A first for Chi-Med; plus Orphazyme, BMS, FDA REMS, Pfizer, Astellas, Alkermes, Osmotica, Quanterix, Ampio and Novartis

...Audentes Therapeutics Inc., an Astellas Pharma Inc. (Tokyo:4503) company, is in development for X-linked myotubular myopathy.Alkermes’...
...3831 returns to FDA for review FDA has accepted an NDA resubmission for ALKS 3831 from Alkermes plc...
BioCentury | Dec 15, 2020
Finance

Dec. 14 Quick Takes: Locanabio raises $100M series B; plus rare bleeding disorder newco Hemab, raises for Rani, CG, InnoSkel, Denovo, Biosion and more

...Partners Acquisition Corp. (NASDAQ:BRPA), a special purpose acquisition company. SPACs re-emerged this year as a viable IPO alternative.Alkermes...
...Healthcare Fund Zheshang Innovest HighTide Therapeutics Inc. Greater Bay Area Homeland Development Fund Hangzhou Tigermed Consulting Co. Ltd. Citic Securities NeuroRx Inc. Alkermes plc China...
BioCentury | Nov 17, 2020
Regulation

Alkermes expects quick resolution to FDA setback for antipsychotic

...By Paul Bonanos, Associate Editor Alkermes expects a swift resolution to a manufacturing issue that led...
...3831, but the company isn’t yet committing to a launch timeline for the antipsychotic combination therapy.Alkermes plc...
...buprenorphine.Alkermes closed up $0.45 to $18.30 on Tuesday.TARGETSMOR (OPRM1) - μ opioid receptor Paul Bonanos samidorphan/olanzapine (ALKS 3831) Alkermes plc...
BioCentury | Oct 12, 2020
Finance

Priothera raises €30 million to develop onetime Novartis candidate in AML transplantation setting

...acquired. The firm had backed Civitas Therapeutics Inc., which housed a Parkinson’s disease program from Alkermes plc...
BioCentury | Oct 10, 2020
Product Development

Oct. 9 Quick Takes: Sobi’s Phase III miss; plus Alkermes, COVAX, Warp Speed-AZ, Lilly-Gates, Pfizer, Everest and Affamed-Kissei

...rights via its $915 million takeout of Dova Pharmaceuticals Inc. last year. FDA panel: labeling sufficient to mitigate Alkermes...
...associated with opioid antagonist action of samidorphan, one of the components of ALKS 3831 from Alkermes plc...
BioCentury | Oct 8, 2020
Product Development

COVAX nears $2B fund-raising goal for equitable vaccine distribution; plus Novartis-Merck KGaA, 10x Genomics, Alkermes, UCB-Aetion, Janpix, BeiGene-BioAtla, Phenomic AI

...CartaNA AB, which is developing in situ RNA analysis technology. FDA to discuss safety, efficacy of Alkermes’...
...disorder candidateBriefing documents released ahead of Friday’s FDA advisory committee meeting to discuss olanzapine/samidorphan from Alkermes plc...
Items per page:
1 - 10 of 1179